Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Chemoradiotherapy
Disease Progression
Female
Fluorodeoxyglucose F18
/ metabolism
Humans
Immune Checkpoint Inhibitors
Lung Neoplasms
/ drug therapy
Male
Neoplasm, Residual
/ drug therapy
Positron Emission Tomography Computed Tomography
Prognosis
Retrospective Studies
Tumor Burden
Durvalumab
Immunotherapy
Metabolic tumor volume
NSCLC
Nivolumab
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
29
07
2021
accepted:
09
10
2021
pubmed:
20
10
2021
medline:
27
4
2022
entrez:
19
10
2021
Statut:
ppublish
Résumé
The PET-derived metabolic tumor volume (MTV) is an independent prognosticator in non-small cell lung cancer (NSCLC) patients. We analyzed the prognostic value of residual MTV (rMTV) after completion of chemoradiotherapy (CRT) in inoperable stage III NSCLC patients with and without immune checkpoint inhibition (ICI). Fifty-six inoperable stage III NSCLC patients (16 female, median 65.0 years) underwent Overall, median follow-up was 52.0 months. Smaller rMTV was associated with longer median PFS (29.3 vs. 10.5 months, p = 0.015), LPFS (49.9 vs. 13.5 months, p = 0.001), and OS (63.0 vs. 23.0 months, p = 0.003). CRT-IO patients compared to CRT patients showed significantly longer median PFS (29.3 vs. 11.2 months, p = 0.034), LPFS (median not reached vs. 14.0 months, p = 0.016), and OS (median not reached vs. 25.2 months, p = 0.007). In the CRT subgroup, smaller rMTV was associated with longer median PFS (33.5 vs. 8.6 months, p = 0.001), LPFS (49.9 vs. 10.1 months, p = 0.001), and OS (63.0 vs. 16.3 months, p = 0.004). In the CRT-IO subgroup, neither PFS, LPFS, nor OS were associated with MTV (p > 0.05 each). The findings were confirmed in subsequent multivariate analyses. In stage III NSCLC, smaller rMTV is highly associated with superior clinical outcome, especially in patients undergoing CRT without ICI. Patients with CRT-IO show significantly improved outcome compared to CRT patients. Of note, clinical outcome in CRT-IO patients is independent of residual MTV. Hence, even patients with large rMTV might profit from ICI despite extensive tumor load.
Sections du résumé
BACKGROUND
The PET-derived metabolic tumor volume (MTV) is an independent prognosticator in non-small cell lung cancer (NSCLC) patients. We analyzed the prognostic value of residual MTV (rMTV) after completion of chemoradiotherapy (CRT) in inoperable stage III NSCLC patients with and without immune checkpoint inhibition (ICI).
METHODS
Fifty-six inoperable stage III NSCLC patients (16 female, median 65.0 years) underwent
RESULTS
Overall, median follow-up was 52.0 months. Smaller rMTV was associated with longer median PFS (29.3 vs. 10.5 months, p = 0.015), LPFS (49.9 vs. 13.5 months, p = 0.001), and OS (63.0 vs. 23.0 months, p = 0.003). CRT-IO patients compared to CRT patients showed significantly longer median PFS (29.3 vs. 11.2 months, p = 0.034), LPFS (median not reached vs. 14.0 months, p = 0.016), and OS (median not reached vs. 25.2 months, p = 0.007). In the CRT subgroup, smaller rMTV was associated with longer median PFS (33.5 vs. 8.6 months, p = 0.001), LPFS (49.9 vs. 10.1 months, p = 0.001), and OS (63.0 vs. 16.3 months, p = 0.004). In the CRT-IO subgroup, neither PFS, LPFS, nor OS were associated with MTV (p > 0.05 each). The findings were confirmed in subsequent multivariate analyses.
CONCLUSION
In stage III NSCLC, smaller rMTV is highly associated with superior clinical outcome, especially in patients undergoing CRT without ICI. Patients with CRT-IO show significantly improved outcome compared to CRT patients. Of note, clinical outcome in CRT-IO patients is independent of residual MTV. Hence, even patients with large rMTV might profit from ICI despite extensive tumor load.
Identifiants
pubmed: 34664091
doi: 10.1007/s00259-021-05584-w
pii: 10.1007/s00259-021-05584-w
pmc: PMC8921088
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1407-1416Informations de copyright
© 2021. The Author(s).
Références
Choi HS, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH, et al. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy. Radiat Oncol. 2017;12:1–8.
Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN guidelines insights: non–small cell lung cancer, version 5.2018. J Natl Comprehen Cancer Network. 2018;16:807–21.
Käsmann L, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S, et al. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer. Strahlenther Onkol. 2018;194:79–90.
pubmed: 29030654
Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annal Oncol. 2017;28:iv1–21.
Taugner J, Käsmann L, Eze C, Dantes M, Roengvoraphoj O, Gennen K, et al. Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy. Translat Lung Cancer Res. 2019;8:593.
Abdel-Rahman O. Outcomes of surgery as part of the management of metastatic non–small-cell lung cancer: a surveillance, epidemiology and end results database analysis. Cancer Invest. 2018;36:238–45.
pubmed: 29775109
Walraven I, Damhuis R, Ten Berge M, Rosskamp M, Van Eycken L, De Ruysscher D, et al. Treatment variation of sequential versus concurrent chemoradiotherapy in stage III non-small cell lung cancer patients in the Netherlands and Belgium. Clin Oncol. 2017;29:e177–85.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–50.
pubmed: 30280658
Käsmann L, Eze C, Dantes M, Roengvoraphoj O, Niyazi M, Belka C, et al. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours—a German radiation oncology survey. Eur J Cancer. 2019;108:50–4.
pubmed: 30648629
Käsmann L, Taugner J, Manapov F. Chemo-/immuno-/radiotherapy combination in treatment of solid cancer. Oncotarget. 2019;10:5387.
pubmed: 31534625
pmcid: 6739220
O’Rourke N, i Figuls MR, Bernadó NF, Macbeth F (2010) Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev
Käsmann L, Eze C, Taugner J, Roengvoraphoj O, Dantes M, Schmidt-Hegemann N-S, et al. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol. 2020;15:1–14.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
pubmed: 26412456
pmcid: 5705936
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–35.
pubmed: 26028407
pmcid: 4681400
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378:2078–92.
pubmed: 29658856
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379:2040–51.
pubmed: 30280635
Foster CC, Sher DJ, Rusthoven CG, Verma V, Spiotto MT, Weichselbaum RR, et al. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol. 2019;14:1–13.
Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann N-S, et al. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol. 2020;15:1–15.
Eze C, Schmidt-Hegemann N-S, Sawicki LM, Kirchner J, Roengvoraphoj O, Käsmann L, et al. PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions. Euro J Nuclear Med Molecul Imag. 2021;48:3975–89.
Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21:581–92.
pubmed: 32171429
Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non–small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.
pubmed: 12815135
Cremonesi M, Gilardi L, Ferrari ME, Piperno G, Travaini LL, Timmerman R, et al. Role of interim 18 F-FDG-PET/CT for the early prediction of clinical outcomes of non-small cell lung cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. Euro J Nuclear Med Molec Imag. 2017;44:1915–27.
Seban R-D, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imag. 2020;47:1147–57. https://doi.org/10.1007/s00259-019-04615-x .
doi: 10.1007/s00259-019-04615-x
Chin AL, Kumar KA, Guo HH, Maxim PG, Wakelee H, Neal JW, et al. Prognostic value of pretreatment FDG-PET parameters in high-dose image-guided radiotherapy for oligometastatic non–small-cell lung cancer. Clin Lung Cancer. 2018;19:e581–8.
pubmed: 29759331
Roengvoraphoj O, Eze C, Wijaya C, Dantes M, Taugner J, Tufman A, et al. How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. Eur J Nucl Med Mol Imag. 2018;45:2103–9.
Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, et al. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. Strahlenther Onkol. 2018;194:107–15. https://doi.org/10.1007/s00066-017-1229-3 .
doi: 10.1007/s00066-017-1229-3
pubmed: 29116336
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—the ETOP NICOLAS trial. Lung Cancer. 2019;133:83–7.
pubmed: 31200833
Im H-J, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imag. 2018;52:5–15.
Goebel J, Hoischen J, Gramsch C, Schemuth HP, Hoffmann A-C, Umutlu L, et al. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria. J Cancer Res Clin Oncol. 2017;143:2527–33.
pubmed: 28825135
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Euro J Cancer. 2009;45:228–47.
Seitz AK, Rauscher I, Haller B, Krönke M, Luther S, Heck MM, et al. Preliminary results on response assessment using 68 Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imag. 2018;45:602–12.
Karin M, Taugner J, Käsmann L, Eze C, Roengvoraphoj O, Tufman A, et al. Association of planning target volume with patient outcome in inoperable stage III NSCLC treated with chemoradiotherapy: a comprehensive single-center analysis. Cancers. 2020;12:3035.
pmcid: 7603086
Wiersma TG, Dahele M, Verbakel WF, van de Ven PM, de Haan PF, Smit EF, et al. Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. Lung Cancer. 2013;80:62–7.
pubmed: 23357464
Ohri N, Bodner WR, Halmos B, Cheng H, Perez-Soler R, Keller SM, et al. 18F-fluorodeoxyglucose/positron emission tomography predicts patterns of failure after definitive chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Rad Oncol Biol Phys. 2017;97:372–80.
Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, et al. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer. Lung Cancer. 2015;87:23–7.
pubmed: 25468149
Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, et al. Prediction of survival by [18F] fluorodeoxyglucose positron emission tomography in patients with locally advanced non–small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013;31:3823.
pubmed: 24043740
pmcid: 3795891
Ohri N, Halmos B, Bodner WR, Cheng H, Garg MK, Gucalp R, et al. Who benefits the most from adjuvant durvalumab after chemoradiotherapy for non-small cell lung cancer? An exploratory analysis Practical Radiation Oncology. 2021;11:e172–9.
pubmed: 33127337
Haakensen V, Horndalsveen H, Nymoen H, Holgersson G, Land LH, Koivunen J, et al. P17. 02 durvalumab after chemoradiotherapy (DART) for NSCLC patients–a phase II translational and biomarker study. J Thoracic Oncol. 2021;16:S351–2.
Park S, Lee Y, Kim T-S, Kim S-k, Han J-Y. Response evaluation after immunotherapy in NSCLC: early response assessment using FDG PET/CT. Medicine. 2020;99:e23815.
pubmed: 33371161
pmcid: 7748304
Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, et al. Comparison between 18F-FDG PET–based and CT-based criteria in non–small cell lung cancer Patients treated with nivolumab. J Nucl Med. 2020;61:990–8.
pubmed: 31806768
Chardin D, Paquet M, Schiappa R, Darcourt J, Bailleux C, Poudenx M, et al. Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer. 2020;8:645.
Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, et al. 18 FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020;47:1158–67.
pubmed: 31760467
Abe T, Saito S, Iino M, Aoshika T, Ryuno Y, Ohta T, et al. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. Thoracic cancer. 2021;12:245–50.
pubmed: 33289347
Taugner J, Käsmann L, Eze C, Tufman A, Reinmuth N, Duell T, et al. Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting. Cancers. 2021;13:1613.
pubmed: 33807324
pmcid: 8037429